ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DXST vs CUVL // FREE CASH FLOW YIELD

Decent Holding Inc (Class A) (NASDAQ) VS. Clinuvel Pharmaceuticals Limited (NASDAQ) • 15-METRIC TALLY: DXST 1 — CUVL 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DXST VS. CUVL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DXST CUVL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 26.20% 81.20% -55.00 CUVL /gross-margins <GO>
Return on Invested Capital (ROIC) — — — TIE /roic <GO>
EV/EBITDA & P/E Valuation — 9.7x — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE — 10.51% — TIE /fcf-yield <GO>
Operating Margin -1.10% 43.40% -44.50 CUVL /operating-margins <GO>
Net Profit Margin -2.50% 37.80% -40.30 CUVL /net-margins <GO>
Revenue Growth (YoY) 12.20% 5.50% +6.70 DXST /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.66% -0.66 CUVL /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 6/9 -4.00 CUVL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 27.1 37.7 -10.54 CUVL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 10.3x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.4M $257.8M -$255.4M CUVL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DXST REV CUVL REV DXST GROSS % CUVL GROSS % DXST FCF CUVL FCF
FY 2025 $12.9M $61.1M 26.2% 81.2% -$3.5M $27.1M
FY 2024 $11.5M $57.9M 27.8% 81.5% -$440.5K $20.1M
FY 2023 $9.4M — — — $1.6M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DXST // BETA —
CUVL // BETA —